10-Q: Psychemedics Corporation Reports Q3 2024 Results and Plans to Go Private

Psychemedics Corporation announced its Q3 2024 financial results, alongside a plan to go private through a reverse/forward stock split and delisting from the Nasdaq.

Summary

• Psychemedics Corporation reported a net loss of $535,000 for the three months ended September 30, 2024, and a net loss of $2.05 million for the nine months ended September 30, 2024.
• Revenue decreased by 9% to $5.175 million for the quarter and 11% to $15.26 million for the nine months compared to the same periods in 2023, primarily due to lower testing volumes.
• The company's gross profit was $2.039 million for the quarter and $5.713 million for the nine months.
• Operating expenses decreased across the board, with general and administrative expenses down 14% for the quarter and 1% for the nine months, marketing and selling expenses down 20% for the quarter and 14% for the nine months, and research and development expenses down 37% for the quarter and 34% for the nine months.
• The company plans to go private through a reverse stock split at a ratio between 1-for-4,000 and 1-for-6,000, followed by a forward stock split at the inverse ratio.
• Stockholders owning fewer shares than the reverse split ratio will receive $2.35 per share in cash.
• The company estimates that approximately 1.3 million shares, or 21% of outstanding shares, will be cashed out at a cost of approximately $3 million, plus $700,000 in transaction expenses.
• The company has entered into a stock purchase agreement with investors to purchase up to 1,595,744 shares at $2.35 per share, for up to $3.75 million, to fund the transaction and for working capital.
• The company anticipates annual savings of approximately $845,000 by going private.

Sentiment

Score: 4

Explanation: The sentiment is negative due to declining revenue, net losses, and the need to go private to reduce costs. However, the company has secured funding for the transaction and anticipates cost savings, which provides a slight positive offset.

Positives

• Operating expenses decreased across all categories, including general and administrative, marketing and selling, and research and development.
• The company anticipates significant cost savings of approximately $845,000 annually by going private.
• The company has secured a stock purchase agreement to fund the going private transaction and provide additional working capital.
• The company's management believes that existing funds, cash flow from operations, and proceeds from the transaction should be adequate to fund the business for at least the next 12 months.

Negatives

• Revenue decreased by 9% for the quarter and 11% for the nine months compared to the same periods in 2023.
• The company reported a net loss of $535,000 for the quarter and $2.05 million for the nine months ended September 30, 2024.
• The company was not in compliance with the fixed charge coverage ratio as of September 30, 2024, but received a waiver from the lender.
• The company's operating activities used net cash of $90,000 for the nine months ended September 30, 2024.

Risks

• The company's future operating results and cash flows could be adversely affected by economic conditions.
• The company may need to seek additional financing sources, but there is no assurance that such financing will be available on acceptable terms.
• The company's plan to go private is subject to stockholder approval and may not be completed.
• Following deregistration, there will be significantly less information available to stockholders and potential investors.
• The company will no longer be subject to certain provisions of the Sarbanes-Oxley Act and the Exchange Act after deregistration.
• Trading in the company's common stock after deregistration and delisting will be more difficult and may cause the value of the stock to decrease.

Future Outlook

The company expects to complete the going private transaction after the Annual Meeting, subject to stockholder approval. The company anticipates annual savings of approximately $845,000 as a result of the transaction. Management believes that existing funds, cash flow from operations, and proceeds from the transaction should be adequate to fund the business for at least the next 12 months.

Management Comments

• The Board has determined the Transaction is in the best interests of all of the Company's stockholders.
• The Company is taking these steps to avoid the substantial cost and expense of being a public reporting company and to focus the Company's resources on enhancing long-term stockholder value.
• Without its public company status, the Company would have an ongoing cost structure befitting its current and foreseeable scale of operations and its management would be able to have an increased focus on core operations.

Industry Context

The company's decision to go private reflects a trend among smaller public companies seeking to reduce the costs and regulatory burdens associated with public reporting. The decrease in revenue and profitability may be indicative of broader economic challenges affecting the drug testing industry, including labor shortages and changing customer priorities.

Comparison to Industry Standards

• It is difficult to compare Psychemedics directly to industry standards without more specific information on its competitors. However, the company's revenue decline and net losses are not uncommon for smaller companies in the current economic climate.
• The company's gross profit margin of 37% for the nine months ended September 30, 2024, is a key metric to compare against competitors in the drug testing industry. Without specific competitor data, it is difficult to assess if this is above or below industry average.
• The company's decision to go private is a significant strategic move that is not directly comparable to industry standards, as most companies seek to remain public to access capital markets.

Corporate Governance

Legal Proceedings

• The company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business.
• The company has a remaining balance of $167 thousand due on or before December 31, 2024, related to a previously disclosed contract dispute with a shipping carrier.

Related Party Transactions

• The company entered into a stock purchase agreement with 3K Limited Partnership, Peter H. Kamin, and related entities, which are considered related parties.

Stakeholder Impact

• Shareholders owning fewer shares than the reverse split ratio will receive $2.35 per share in cash, while continuing shareholders will not receive cash for fractional shares.
• Employees may be affected by the company's cost-cutting measures and the transition to a private company.
• Customers may experience changes in service or pricing as the company adjusts its operations.
• Creditors may be affected by the company's debt obligations and financial performance.
• Suppliers may be affected by changes in the company's purchasing patterns.

Next Steps

• The company will hold its 2024 Annual Meeting of Stockholders on November 25, 2024, to vote on the going private transaction.
• The company will determine the final reverse stock split ratio prior to the closing of the stock sale.
• The company will terminate the registration of its common stock with the SEC and delist from the Nasdaq Capital Market after the Annual Meeting, subject to stockholder approval.

Key Dates

Keywords

Psychemedics, going private, reverse stock split, delisting, financial results, Q3 2024, stock purchase agreement, drug testing, revenue, net loss